Close Menu

NEW YORK – LevitasBio, a Stanford spinout commercializing a cell purification and separation technology based on magnetic levitation, said on Wednesday that it has raised $18 million in a Series B financing round.

Thalys Medical Group led the round, joined by Series A lead investor Decheng Capital.

LevitasBio also said it would form a China-based joint venture with Thalys to further develop, manufacture, and distribute the firm's technology in that country.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.